A surprising no to both multiple myeloma uses puts the ball in the FDA's court.
ApexOnco Front Page
Recent articles
The group has canned its first-generation project, hoping that a follow-on will reach more patients.
Can activity at CTLA-4 be added to PD-1 x VEGF blockade?
Skyscraper-07 fails, while a Poseida-originated Car-T is also scrapped.
The curtain lifts on Veritac-2, rusfertide, and another double plenary for Astra.
Meanwhile, the company plays down the risk of Jaypirca’s CLL approval being rescinded.
The PD-1 x VEGF molecule's latest win comes from Akeso's Harmoni-6 trial.
Gilead’s TROP2 ADC prevails in Ascent-04, in first-line PD-L1-positive TNBC.
